Anthropic has acquired Mithril Medicine, a one-person biotechnology startup developing treatments for rare muscular dystrophies, signaling a deeper push into internal drug discovery.
The transaction brings Mithril founder and sole operator Cody Tranbarger into Anthropic’s life sciences division, the company announced Tuesday alongside early data from collaborative pharmaceutical initiatives.
Tranbarger previously leveraged Anthropic’s flagship AI system, Claude, to oversee administrative logistics, legal contracts, and laboratory workflows across 11 partner facilities.
Working as an independent researcher, Tranbarger advanced experimental therapy targeting LAMA2-related congenital muscular dystrophy from initial ideation to positive preclinical murine trials in under 18 months. Anthropic indicated that if laboratory milestones proceed without interruption, the lead candidate could begin human clinical trials by late 2028.
Alongside the buyout, Anthropic published non-peer-reviewed results evaluating Claude’s utility across six external industry partners: Bristol Myers Squibb, BigHat Biosciences, Divergence Labs, Enveda, Generate Biomedicines, and venture firm The Column Group. While the vast majority of assets remain in early preclinical stages, the initial data demonstrate notable operational efficiencies and accelerated molecular design timelines.
At Generate Biomedicines, computational biologists utilized Claude Code to engineer a synthetic component for chimeric antigen receptor (CAR) T-cell therapies. The resulting sequence proved roughly 70% shorter than standard industry analogs while enabling engineered immune cells to express nearly ten times as many cancer-targeting receptors during bench evaluation.
Other collaborative results reflected similar speed in antibody modeling. Divergence Labs deployed the system to screen approximately 35,000 antibody candidates within a month for a food allergy candidate, yielding lead molecules that displaced target IgE proteins more effectively than baseline controls.
Concurrently, BigHat Biosciences assayed 1,010 model-guided variants across two antibody fragments over ten weeks, isolating variations exhibiting up to a tenfold gain in target affinity.
Beyond biological design, Claude demonstrated significant reductions in pharmaceutical administrative workloads. At Enveda, where analytical chemists historically devoted three-quarters of their working hours to regulatory compliance, the model processed 1,061 pages of complex manufacturing records in less than three hours — down from over 25 hours — identifying all 11 compliance issues found by human auditors alongside seven unspotted discrepancies.
Enveda noted the system also drafted an initial clinical application submission in four hours, a task conventionally requiring three months.
Global pharmaceutical maker Bristol Myers Squibb is currently deploying Claude to analyze early-stage clinical trial designs and model probability-of-success metrics.
Dr. Michael Pourdehnad, senior vice president of early clinical development at Bristol Myers, said an initial analysis typically demanding days of manual work was returned from a single prompt. Bristol Myers and Anthropic intend to broaden the partnership in 2027.
The acquisition and research disclosures follow Anthropic’s launch of a dedicated Bay Area biology laboratory in September, underscoring tech firms’ growing ambition to modernize the protracted, multibillion-dollar pipeline of modern therapeutics.
